High Tolerability, Favorable Safety, and Subjects' Preference for a Single 200 mg/2 mL Tildrakizumab Injection: A Phase I, Open-Label, Randomized Crossover Trial in Healthy Volunteers

Kokolakis G, Kreis G, Falqués M, Aparici M, Sondermann W (2022)

Publication Type: Journal article

Publication year: 2022

Journal

Dermatology and Therapy Springer Verlag

Book Volume: 12

Pages Range: 2135-2144

Journal Issue: 9

DOI: 10.1007/s13555-022-00789-9

Abstract

Introduction: Tildrakizumab 200 mg/2 mL pre-filled syringe is a new preparation of tildrakizumab that is developed to facilitate patients’ compliance. This phase I clinical trial compares the local tolerability, safety, and subjects’ preferred method of administration of tildrakizumab when administered as a new single 200 mg/2 mL subcutaneous injection or as two 100 mg/1 mL subcutaneous injections in healthy subjects. Methods: Visual analogue scores were used to self-assess injection site pain immediately (< 1 min) after each administration and at 1 h and 48 h after each administration. Treatment injection site reactions were assessed at 1 h and 48 h after each administration. Treatment safety was monitored throughout the study period. Subjects’ preferred method of administration was assessed 4 weeks after the last administration (day 56). Results: No statistically significant difference in visual analogue scores and injection site reactions was detected between the two treatments. Treatment-emergent adverse events were mild, and there were no deaths or serious adverse events. Most subjects (61.5%) preferred the treatment when administered as a single 200 mg/2 mL subcutaneous injection rather than as two 100 mg/mL subcutaneous injections. Conclusions: Administration of 200 mg tildrakizumab as a single 2 mL subcutaneous injection was safe, well tolerated, and preferred over two separate 100 mg/1 mL subcutaneous injections by healthy subjects. Eudract No. 2020-000183-37.

Involved external institutions

Charité - Universitätsmedizin Berlin DE Germany (DE) Almirall, S.A. ES Spain (ES) Universitätsklinikum Essen DE Germany (DE)

How to cite

APA:

Kokolakis, G., Kreis, G., Falqués, M., Aparici, M., & Sondermann, W. (2022). High Tolerability, Favorable Safety, and Subjects' Preference for a Single 200 mg/2 mL Tildrakizumab Injection: A Phase I, Open-Label, Randomized Crossover Trial in Healthy Volunteers. Dermatology and Therapy, 12(9), 2135-2144. https://doi.org/10.1007/s13555-022-00789-9

MLA:

Kokolakis, Georgios, et al. "High Tolerability, Favorable Safety, and Subjects' Preference for a Single 200 mg/2 mL Tildrakizumab Injection: A Phase I, Open-Label, Randomized Crossover Trial in Healthy Volunteers." Dermatology and Therapy 12.9 (2022): 2135-2144.

BibTeX: Download